Sign Up to like & get recommendations! 0
Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.6093
Abstract: This study examines the reintervention rate associated with treatment failures and device malfunctions at 1, 3, and 5 years after sacral neuromodulation surgery. read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24075
Abstract: Sacral neuromodulation (SNM) is a standard therapy for refractory overactive bladder (OAB). Traditionally, SNM placement involves placement of an S3 lead with 1–3 weeks of testing before considering a permanent implant. Given the potential risk… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24476
Abstract: To compare treatment success rate in terms of improvement of bladder overactivity between unilateral and bilateral sacral neuromodulation testing. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24593
Abstract: Pulse width (PW) influences neuromodulation by its impact on nerve fiber recruitment. A paucity of data regarding the manipulation of PW in sacral neuromodulation (SNM) exists. This study describes the clinical features and outcomes of… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24615
Abstract: Sacral neuromodulation (SNM) is a guideline‐recommended treatment with proven therapeutic benefit for urinary urgency incontinence (UUI) patients. The Axonics® System is the first Food and Drug Administration‐approved rechargeable SNM system and is designed to deliver… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24670
Abstract: Sacral neuromodulation (SNM) and Botulinum toxin A (BoNT‐A) injections are well‐known third‐line treatment options in patients with refractory overactive bladder (OAB). Our aim is to evaluate the success rate of SNM in patients who received… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24698
Abstract: A ≥50% subjective improvement in urinary symptoms during sacral neuromodulation testing (SNM‐I) is currently used as the indication for progression to second‐stage implantation (SNM‐II). While most patients will have successful SNM‐I and proceed to SNM‐II,… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Neurourology and urodynamics"
DOI: 10.1002/nau.24756
Abstract: AIMS Sacral neuromodulation (SNM) has successfully treated patients with functional urinary and/or bowel disorders for more than two decades. Historically, patients with the InterStim system (Medtronic) were contraindicated for Magnetic Resonance Imaging (MRI) scans. In 2012,… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24933
Abstract: To define radiologically anatomic measurements for the S3 foramen and develop an efficient and straightforward implantation protocol for sacral neuromodulation (SNM) in a southern Chinese population. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Neurourology and Urodynamics"
DOI: 10.1002/nau.24955
Abstract: Sacral neuromodulation (SNM) is third‐line therapy approved for urge urinary incontinence (UUI) and urgency, and nonobstructive urinary retention. Multiple sclerosis (MS) patients often suffer from neurogenic lower urinary tract dysfunction (NLUTD). The utility of SNM… read more here.